Suzhou-based EOSVISION Ltd has reportedly raised close to RMB 100 million (USD 13.78 million) in a Series A financing round, led by Dalton Venture. The proceeds from this investment will be allocated to bolster the company’s research and development (R&D), clinical studies, global development, regulatory filing, and marketing efforts for its suite of artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelial cells, and artificial dermis.
EOSVISION’s Commitment to Ophthalmic Regenerative Medicine
Founded in 2020, EOSVISION is dedicated to the development of new bio-modified materials for ophthalmic implantable medical devices and regenerative medical devices. The company’s focus on innovation in this field addresses the unmet needs in ophthalmology and has the potential to transform patient care through advanced medical solutions.
Expanding Ophthalmic Product Portfolio
The company’s product portfolio includes a range of cutting-edge ophthalmic products, from artificial biomimetic corneas to implantable contact lenses and artificial corneal endothelial cells. These products are designed to offer patients improved vision and quality of life through innovative regenerative medicine techniques.-Fineline Info & Tech
